-
1
-
-
84905487277
-
Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome
-
Brito-Zerón, P.; Ramos-Casals, M. Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome. Curr. Opin. Rheumatol. 2014, 26, 520-527, doi:10.1097/BOR.0000000000000096.
-
(2014)
Curr. Opin. Rheumatol.
, vol.26
, pp. 520-527
-
-
Brito-Zerón, P.1
Ramos-Casals, M.2
-
2
-
-
0021002653
-
Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjögren’s syndrome
-
Fox, R.I.; Adamson, T.C., 3rd; Fong, S.; Young, C.; Howell, F.V. Characterization of the phenotype and function of lymphocytes infiltrating the salivary gland in patients with primary Sjögren’s syndrome. Diagn. Immunol. 1983, 1, 233-239.
-
(1983)
Diagn. Immunol.
, vol.1
, pp. 233-239
-
-
Fox, R.I.1
Adamson, T.C.2
Fong, S.3
Young, C.4
Howell, F.V.5
-
3
-
-
0038276049
-
TH1-TH2: A procrustean paradigm
-
Cor, D.O.; Rose, N.R.; Greenspan, N.S. TH1-TH2: A procrustean paradigm. Nat. Immunol. 2003, 4, 503-505, doi:10.1038/ni0603-503.
-
(2003)
Nat. Immunol
, vol.4
, pp. 503-505
-
-
Cor, D.O.1
Rose, N.R.2
Greenspan, N.S.3
-
4
-
-
84883448195
-
Advances in understanding the pathogenesis of primary Sjögren’s syndrome
-
Nocturne, G.; Mariette, X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat. Rev. Rheumatol. 2013, 9, 544-556, doi:10.1038/nrrheum.2013.110.
-
(2013)
Nat. Rev. Rheumatol.
, vol.9
, pp. 544-556
-
-
Nocturne, G.1
Mariette, X.2
-
5
-
-
84901256461
-
The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren’s syndrome: A critical review
-
Sumida, T.; Tsuboi, H.; Iizuka, M.; Hirota, T.; Asashima, H.; Matsumoto, I. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren’s syndrome: A critical review. J. Autoimmun. 2014, 51, 44-50, doi:10.1016/j.jaut.2013.12.012.
-
(2014)
J. Autoimmun.
, vol.51
, pp. 44-50
-
-
Sumida, T.1
Tsuboi, H.2
Iizuka, M.3
Hirota, T.4
Asashima, H.5
Matsumoto, I.6
-
6
-
-
84859709877
-
CD4+T cells: Differentiation and functions
-
Luckheeram, R.V.; Zhou, R.; Verma, A.D.; Xia, B. CD4+T cells: Differentiation and functions. Clin. Dev. Immunol. 2012, 2012, 925135, doi:10.1155/2012/925135.
-
(2012)
Clin. Dev. Immunol.
, vol.2012
, pp. 925135
-
-
Luckheeram, R.V.1
Zhou, R.2
Verma, A.D.3
Xia, B.4
-
7
-
-
69349093225
-
Interleukin-17 and type 17 helper T cells
-
Miossec, P.; Korn, T.; Kuchroo, V.K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 2009, 361, 888-898, doi:10.1056/NEJMra0707449.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 888-898
-
-
Miossec, P.1
Korn, T.2
Kuchroo, V.K.3
-
8
-
-
84902477298
-
CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjögren’s syndrome
-
Jin, L.; Yu, D.; Li, X.; Yu, N.; Li, X.; Wang, Y.; Wang, Y. CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjögren’s syndrome. Int. J. Clin. Exp. Pathol. 2014, 7, 1988-1996.
-
(2014)
Int. J. Clin. Exp. Pathol.
, vol.7
, pp. 1988-1996
-
-
Jin, L.1
Yu, D.2
Li, X.3
Yu, N.4
Li, X.5
Wang, Y.6
Wang, Y.7
-
9
-
-
77956273246
-
Proinflammatory T helper type 17 cells are effective B-cell helpers
-
Mitsdoerffer, M.; Lee, Y.; Jäger, A.; Kim, H.J.; Korn, T.; Kolls, J.K.; Cantor, H.; Bettelli, E.; Kuchroo, V.K. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 2010, 107, 14292-14297, doi:10.1073/pnas.1009234107.
-
(2010)
Proc. Natl. Acad. Sci. USA
, vol.107
, pp. 14292-14297
-
-
Mitsdoerffer, M.1
Lee, Y.2
Jäger, A.3
Kim, H.J.4
Korn, T.5
Kolls, J.K.6
Cantor, H.7
Bettelli, E.8
Kuchroo, V.K.9
-
10
-
-
77950432271
-
Age-related T-cell cytokine profile parallels corneal disease severity in Sjögren’s syndrome-like keratoconjunctivitis sicca in CD25KO mice
-
De Paiva, C.S.; Hwan, C.S.; Pitcher, J.D., 3rd.; Pangelinan, S,B.; Rahimy, E.; Chen, W.; Yoon, K.C.; Farley, W.J.; Niederkorn, J.Y.; Stern, M.E.; et al. Age-related T-cell cytokine profile parallels corneal disease severity in Sjögren’s syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rhuematology 2010, 49, 246-258, doi:10.1093/rheumatology/kep357.
-
(2010)
Rhuematology
, vol.49
, pp. 246-258
-
-
De Paiva, C.S.1
Hwan, C.S.2
Pitcher, J.D.3
Pangelinan, S.B.4
Rahimy, E.5
Chen, W.6
Yoon, K.C.7
Farley, W.J.8
Niederkorn, J.Y.9
Stern, M.E.10
-
11
-
-
31344466838
-
Sjögren’s syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease
-
Gao, J.; Killedar, S.; Cornelius, J.G.; Nguyen, C.; Cha, S.; Peck, A.B. Sjögren’s syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J. Autoimmun. 2006, 26, 90-103.
-
(2006)
J. Autoimmun.
, vol.26
, pp. 90-103
-
-
Gao, J.1
Killedar, S.2
Cornelius, J.G.3
Nguyen, C.4
Cha, S.5
Peck, A.B.6
-
12
-
-
78650793542
-
IL17: Potential therapeutic target in Sjögren’s syndrome using adenovirus-mediated gene transfer
-
Nguyen, C.Q.; Yin, H.; Lee, B.H.; Chiorini, J.A.; Peck, A.B. IL17: Potential therapeutic target in Sjögren’s syndrome using adenovirus-mediated gene transfer. Lab. Investig. 2011, 91, 54-62, doi:10.1038/labinvest.2010.164.
-
(2011)
Lab. Investig.
, vol.91
, pp. 54-62
-
-
Nguyen, C.Q.1
Yin, H.2
Lee, B.H.3
Chiorini, J.A.4
Peck, A.B.5
-
13
-
-
85006074130
-
Sexual dimorphic function of IL-17 in salivary gland dysfunction of the C57BL/6.NOD-Aec1Aec2 model of Sjögren’s syndrome
-
Voigt, A.; Esfandiary, L.; Wanchoo, A.; Glenton, P.; Donate, A.; Craft, W.F.; Craft, S.L.; Nguyen, C.Q. Sexual dimorphic function of IL-17 in salivary gland dysfunction of the C57BL/6.NOD-Aec1Aec2 model of Sjögren’s syndrome. Sci. Rep. 2016, 6, 38717, doi:10.1038/srep38717.
-
(2016)
Sci. Rep.
, vol.6
, pp. 38717
-
-
Voigt, A.1
Esfandiary, L.2
Wanchoo, A.3
Glenton, P.4
Donate, A.5
Craft, W.F.6
Craft, S.L.7
Nguyen, C.Q.8
-
14
-
-
84886067284
-
Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics
-
Van den Berg, W.B.; McInnes, I.B. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin. Arthritis Rheum. 2013, 43, 158-170, doi:10.1016/j. semarthrit.2013.04.006.
-
(2013)
Semin. Arthritis Rheum.
, vol.43
, pp. 158-170
-
-
Van den Berg, W.B.1
McInnes, I.B.2
-
15
-
-
84934998034
-
Th17 cells play a critical role in the development of experimental Sjögren’s syndrome
-
Lin, X.; Rui, K.; Deng, J.; Tian, J.; Wang, X.; Wang, S.; Ko, K.H.; Jiao, Z.; Chan, V.S.; Lau, C.S.; et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann. Rheum. Dis. 2015, 74, 1302-1310, doi:10.1136/annrheumdis-2013-204584.
-
(2015)
Ann. Rheum. Dis.
, vol.74
, pp. 1302-1310
-
-
Lin, X.1
Rui, K.2
Deng, J.3
Tian, J.4
Wang, X.5
Wang, S.6
Ko, K.H.7
Jiao, Z.8
Chan, V.S.9
Lau, C.S.10
-
16
-
-
84991109203
-
RORγt antagonist suppresses M3 muscarinic acetylcholine receptorinduced Sjögren’s syndrome-like sialadenitis
-
Tahara, M.; Tsuboi, H.; Segawa, S.; Asashima, H.; Iizuka-Koga, M.; Hirota, T.; Takahashi, H.; Kondo, Y.; Matsui, M.; Matsumoto, I.; et al. RORγt antagonist suppresses M3 muscarinic acetylcholine receptorinduced Sjögren’s syndrome-like sialadenitis. Clin. Exp. Immunol. 2017, 187, 213-224, doi:10.1111/cei.12868.
-
(2017)
Clin. Exp. Immunol.
, vol.187
, pp. 213-224
-
-
Tahara, M.1
Tsuboi, H.2
Segawa, S.3
Asashima, H.4
Iizuka-Koga, M.5
Hirota, T.6
Takahashi, H.7
Kondo, Y.8
Matsui, M.9
Matsumoto, I.10
-
17
-
-
76049096595
-
The numbers of Foxp3+ Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren’s syndrome
-
Sarigul, M.; Yazusiz, V.; Bassorgun, C.I.; Ulker, M.; Avci, A.B.; Erbasan, F.; Ulker, M.; Gelen, T.; Gorczynski, R.M.; Terzioglu, E. The numbers of Foxp3+ Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren’s syndrome. Lupus 2010, 19, 138-145, doi:10.1177/0961203309348234.
-
(2010)
Lupus
, vol.19
, pp. 138-145
-
-
Sarigul, M.1
Yazusiz, V.2
Bassorgun, C.I.3
Ulker, M.4
Avci, A.B.5
Erbasan, F.6
Ulker, M.7
Gelen, T.8
Gorczynski, R.M.9
Terzioglu, E.10
-
18
-
-
55349085462
-
Foxp3+ T-regulatory cells in Sjögren’s syndrome: Correlation with the grade of the autoimmune lesion and certain adverse prognostic factors
-
Christodoulou, M.I.; Kapsogeorgou, E.K.; Moutsopoulos, N.M.; Moutsopoulos, H.M. Foxp3+ T-regulatory cells in Sjögren’s syndrome: Correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am. J. Pathol. 2008, 173, 1389-1396, doi:10.2353/ajpath.2008.080246.
-
(2008)
Am. J. Pathol.
, vol.173
, pp. 1389-1396
-
-
Christodoulou, M.I.1
Kapsogeorgou, E.K.2
Moutsopoulos, N.M.3
Moutsopoulos, H.M.4
-
19
-
-
67651236911
-
Cells with regulatory function of the innate and adaptive immune system in primary Sjögren’s syndrome
-
Szodoray, P.; Papp, G.; Horvath, I.F.; Barath, S.; Sipka, S.; Nakken, B.; Zeher, M. Cells with regulatory function of the innate and adaptive immune system in primary Sjögren’s syndrome. Clin. Exp. Immunol. 2009, 157, 343-349, doi:10.1111/j.1365-2249.2009.
-
(2009)
Clin. Exp. Immunol.
, vol.157
, pp. 343-349
-
-
Szodoray, P.1
Papp, G.2
Horvath, I.F.3
Barath, S.4
Sipka, S.5
Nakken, B.6
Zeher, M.7
-
20
-
-
84898924344
-
Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjögren’s syndrome
-
Fei, Y.; Zhang, W.; Lin, D.; Wu, C.; Li, M.; Zhao, Y.; Zeng, X.; Zhang, F. Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjögren’s syndrome. Clin. Rheumatol. 2014, 33, 523-529, doi:10.1007/s10067-013-2476-z.
-
(2014)
Clin. Rheumatol.
, vol.33
, pp. 523-529
-
-
Fei, Y.1
Zhang, W.2
Lin, D.3
Wu, C.4
Li, M.5
Zhao, Y.6
Zeng, X.7
Zhang, F.8
-
21
-
-
70349244787
-
Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis
-
Katsifis, G.E.; Rekka, S.; Moutsopoulos, N.M.; Pillemer, S.; Wahl, S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren’s syndrome immunopathogenesis. Am. J. Pathol. 2009, 175, 1167-1177, doi:10.2353/ajpath.2009.
-
(2009)
Am. J. Pathol.
, vol.175
, pp. 1167-1177
-
-
Katsifis, G.E.1
Rekka, S.2
Moutsopoulos, N.M.3
Pillemer, S.4
Wahl, S.M.5
-
22
-
-
84855350256
-
Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren’s syndrome
-
Ciccia, F.; Guggino, G.; Rizzo, A.; Ferrante, A.; Raimondo, S.; Giardina, A.; Dieli, F.; Campisi, G.; Alessandro, R.; Triolo, G. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren’s syndrome. Ann. Rheum. Dis. 2012, 71, 295-301, doi:10.1136/ard.2011.154013.
-
(2012)
Ann. Rheum. Dis.
, vol.71
, pp. 295-301
-
-
Ciccia, F.1
Guggino, G.2
Rizzo, A.3
Ferrante, A.4
Raimondo, S.5
Giardina, A.6
Dieli, F.7
Campisi, G.8
Alessandro, R.9
Triolo, G.10
-
23
-
-
53149131365
-
Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18
-
Sakai, A.; Sugawara, Y.; Kuroishi, T.; Sasano, T.; Sugawara, S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J. Immunol. 2008, 181, 2898-906.
-
(2008)
J. Immunol.
, vol.181
, pp. 2898-2906
-
-
Sakai, A.1
Sugawara, Y.2
Kuroishi, T.3
Sasano, T.4
Sugawara, S.5
-
24
-
-
84864833865
-
Th17 response and inflammatory autoimmune diseases
-
Waite, J.C.; Skokos, D. Th17 response and inflammatory autoimmune diseases. Int. J. Inflam. 2012, 2012, 819467, doi:10.1155/2012/819467.
-
(2012)
Int. J. Inflam.
, vol.2012
, pp. 819467
-
-
Waite, J.C.1
Skokos, D.2
-
25
-
-
36849036211
-
IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner
-
Wei, L.; Lauesnce, A.; Elias, K.M.; O’Shea, J.J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 2007, 282, 34605-34610.
-
(2007)
J. Biol. Chem.
, vol.282
, pp. 34605-34610
-
-
Wei, L.1
Lauesnce, A.2
Elias, K.M.3
O’Shea, J.J.4
-
26
-
-
84861210702
-
IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis
-
Attridge, K.; Wang, C.J.; Wardzinski, L.; Kenefeck, R.; Chamberlain, J.L.; Manzotti, C.; Kopf, M.; Walker, L.S. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 2012, 119, 4656-4664, doi:10.1182/blood-2011-10-388546.
-
(2012)
Blood
, vol.119
, pp. 4656-4664
-
-
Attridge, K.1
Wang, C.J.2
Wardzinski, L.3
Kenefeck, R.4
Chamberlain, J.L.5
Manzotti, C.6
Kopf, M.7
Walker, L.S.8
-
27
-
-
84855445128
-
Impact of interleukin-21 in the pathogenesis of primary Sjögren’s syndrome: Increased serum levels of interleukin-21 and its expression in the labial salivary glands
-
Kang, K.Y.; Kim, H.O.; Kwok, S.K.; Ju, J.H.; Park, K.S.; Sun, D.I.; Jhun, J.Y.; Oh, H.J.; Park, S.H.; Kim, H.Y. Impact of interleukin-21 in the pathogenesis of primary Sjögren’s syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res. Ther. 2011, 13, R179, doi:10.1186/ar3504
-
(2011)
Arthritis Res. Ther.
, vol.13
, pp. R179
-
-
Kang, K.Y.1
Kim, H.O.2
Kwok, S.K.3
Ju, J.H.4
Park, K.S.5
Sun, D.I.6
Jhun, J.Y.7
Oh, H.J.8
Park, S.H.9
Kim, H.Y.10
-
28
-
-
79952675131
-
Follicular helper CD4 T cells (TFH)
-
Crotty, S. Follicular helper CD4 T cells (TFH). Ann. Rev. Immunol. 2011, 29, 621-663, doi:10.1146/annurevimmunol-031210-101400.
-
(2011)
Ann. Rev. Immunol.
, vol.29
, pp. 621-663
-
-
Crotty, S.1
-
29
-
-
77957256910
-
The elusive identity of T follicular helper cells
-
Yu, D.; Vinuesa, C.G. The elusive identity of T follicular helper cells. Trends Immunol. 2010, 31, 377-383, doi:10.1016/j.it.2010.07.001.
-
(2010)
Trends Immunol.
, vol.31
, pp. 377-383
-
-
Yu, D.1
Vinuesa, C.G.2
-
30
-
-
37649013005
-
Sjögren’s syndrome: A quintessential B cell-induced autoimmune disease
-
Youinou, P. Sjögren’s syndrome: A quintessential B cell-induced autoimmune disease. Jt. Bone Spine 2008, 75, 1-2.
-
(2008)
Jt. Bone Spine
, vol.75
, pp. 1-2
-
-
Youinou, P.1
-
31
-
-
84863497528
-
Topical and systemic medications for the treatment of primary Sjögren’s syndrome
-
Ramos-Casals, M.; Brito-Zerón, P.; Sisó-Almirall, A.; Bosch, X.; Tzioufas, A.G. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat. Rev. Rheumatol. 2012, 8, 399-411, doi:10.1038/nrrheum.2012.53.
-
(2012)
Nat. Rev. Rheumatol.
, vol.8
, pp. 399-411
-
-
Ramos-Casals, M.1
Brito-Zerón, P.2
Sisó-Almirall, A.3
Bosch, X.4
Tzioufas, A.G.5
-
32
-
-
77950538947
-
Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trail
-
Meijer, J.M.; Meiners, P.M.; Vissink, A.; Spijkervet, F.K.; Abdulahad, W.; Kamminga, N.; Brouwer, E.; Kallenberg, C.G.; Bootsma, H. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trail. Arthritis Rheum. 2010, 62, 960-968, doi:10.1002/art.27314.
-
(2010)
Arthritis Rheum.
, vol.62
, pp. 960-968
-
-
Meijer, J.M.1
Meiners, P.M.2
Vissink, A.3
Spijkervet, F.K.4
Abdulahad, W.5
Kamminga, N.6
Brouwer, E.7
Kallenberg, C.G.8
Bootsma, H.9
-
33
-
-
54349116244
-
Reduction of fatigue in Sjögren’s syndrome with rituximab results of a randomized, double-blind, placebocontrolled pilot study
-
Dass, S.; Bowman, S.J.; Vital, E.M.; Ikeda, K.; Pease, C.T.; Hamburger, J.; Richards, A.; Rauz, S.; Emery, P. Reduction of fatigue in Sjögren’s syndrome with rituximab results of a randomized, double-blind, placebocontrolled pilot study. Ann. Rheum. Dis. 2008, 67, 1541-1544, doi:10.1136/ard.2007.083865.
-
(2008)
Ann. Rheum. Dis.
, vol.67
, pp. 1541-1544
-
-
Dass, S.1
Bowman, S.J.2
Vital, E.M.3
Ikeda, K.4
Pease, C.T.5
Hamburger, J.6
Richards, A.7
Rauz, S.8
Emery, P.9
-
34
-
-
84877611272
-
Club rhumatismes et inflammations and the french society of rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: Results in 78 patients of the AutoImmune and Rituximab registry
-
Gottenberg, J.E.; Cinquetti, G.; Larroche, C.; Combe, B.; Hachulla, E.; Meyer, O.; Pertuiset, E.; Kaplanski, G.; Chiche, L.; Berthelot, J.M.; et al. Club rhumatismes et inflammations and the french society of rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. 2013, 72, 1026-1031, doi:10.1136/annrheumdis-2012-202293.
-
(2013)
Ann. Rheum. Dis.
, vol.72
, pp. 1026-1031
-
-
Gottenberg, J.E.1
Cinquetti, G.2
Larroche, C.3
Combe, B.4
Hachulla, E.5
Meyer, O.6
Pertuiset, E.7
Kaplanski, G.8
Chiche, L.9
Berthelot, J.M.10
-
35
-
-
77949442819
-
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial)
-
Emery, P.; Durez, P.; Dougados, M.; Legerton, C.W.; Becker, J.C.; Vratsanos, G.; Genant, H.K.; Peterfy, C.; Mitra, P.; Overfield, S.; et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial). Ann. Rheum. Dis. 2010, 69, 510-516, doi:10.1136/ard.2009.119016.
-
(2010)
Ann. Rheum. Dis.
, vol.69
, pp. 510-516
-
-
Emery, P.1
Durez, P.2
Dougados, M.3
Legerton, C.W.4
Becker, J.C.5
Vratsanos, G.6
Genant, H.K.7
Peterfy, C.8
Mitra, P.9
Overfield, S.10
-
36
-
-
65349176911
-
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
-
Westhovens, R.; Robles, M.; Ximenes, A.C.; Nayiager, S.; Wollenhaupt, J.; Durez, P.; Gomez-Reino, J.; Grassi, W.; Haraoui, B.; Shergy, W.; et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009, 68, 1870-1877, doi:10.1136/ard.2008.101121.
-
(2009)
Ann. Rheum. Dis.
, vol.68
, pp. 1870-1877
-
-
Westhovens, R.1
Robles, M.2
Ximenes, A.C.3
Nayiager, S.4
Wollenhaupt, J.5
Durez, P.6
Gomez-Reino, J.7
Grassi, W.8
Haraoui, B.9
Shergy, W.10
-
37
-
-
33745291091
-
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial
-
Kremer, J.M.; Genant, H.K.; Moreland, L.W.; Russell, A.S.; Emery, P.; Abud-Mendoza, C.; Szechinski, J.; Li, T.; Ge, Z.; Becker, J.C.; et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 2006, 144, 865-876.
-
(2006)
Ann. Intern. Med.
, vol.144
, pp. 865-876
-
-
Kremer, J.M.1
Genant, H.K.2
Moreland, L.W.3
Russell, A.S.4
Emery, P.5
Abud-Mendoza, C.6
Szechinski, J.7
Li, T.8
Ge, Z.9
Becker, J.C.10
-
38
-
-
24944498854
-
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
-
Genovese, M.C.; Becker, J.C.; Schiff, M.; Luggen, M.; Sherrer, Y.; Kremer, J.; Birbara, C.; Box, J.; Natarajan, K.; Nuamah, I.; et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005, 353, 1114-1123.
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 1114-1123
-
-
Genovese, M.C.1
Becker, J.C.2
Schiff, M.3
Luggen, M.4
Sherrer, Y.5
Kremer, J.6
Birbara, C.7
Box, J.8
Natarajan, K.9
Nuamah, I.10
-
39
-
-
84924370171
-
Efficacy and safety of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis: Rheumatoid arthritis with orencia trial toward Sjögren’s syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks
-
Tsuboi, H.; Matsumoto, I.; Hagiwara, S.; Hirota, T.; Takahashi, H.; Ebe, H.; Yokosawa, M.; Hagiya, C.; Asashima, H.; Takai, C.; et al. Efficacy and safety of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis: Rheumatoid arthritis with orencia trial toward Sjögren’s syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks. Mod. Rheumatol. 2015, 25, 187-193, doi:10.2109/14397595.2014.951144.
-
(2015)
Mod. Rheumatol.
, vol.25
, pp. 187-193
-
-
Tsuboi, H.1
Matsumoto, I.2
Hagiwara, S.3
Hirota, T.4
Takahashi, H.5
Ebe, H.6
Yokosawa, M.7
Hagiya, C.8
Asashima, H.9
Takai, C.10
-
40
-
-
84941023497
-
Th17 cells in autoimmune diseases
-
Han, L.; Yang, J.; Wang, X.; Li, D.; Lv, L.; Li, B. Th17 cells in autoimmune diseases. Front. Med. 2015, 9, 10-19, doi:10.1007/s11684-015-0388-9.
-
(2015)
Front. Med.
, vol.9
, pp. 10-19
-
-
Han, L.1
Yang, J.2
Wang, X.3
Li, D.4
Lv, L.5
Li, B.6
-
41
-
-
84975743646
-
IL-17 in chronic inflammation: From discovery to targeting
-
Beringer, A.; Noack, M.; Miossec, P. IL-17 in chronic inflammation: From discovery to targeting. Trends Mol. Med. 2016, 22, 230-241, doi:10.1016/j.molmed.2016.01.001.
-
(2016)
Trends Mol. Med.
, vol.22
, pp. 230-241
-
-
Beringer, A.1
Noack, M.2
Miossec, P.3
-
42
-
-
77958072084
-
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis
-
Hueber, W.; Patel, D.D.; Dryja, T.; Wright, A.M.; Koroleva, I.; Bruin, G.; Antoni, C.; Draelos, Z.; Gold, M.H.; Psoriasis Study Group; et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2, 52ra72, doi:10.1126/scitranslmed.3001107.
-
(2010)
Sci. Transl. Med.
, vol.2
, pp. 52ra72
-
-
Hueber, W.1
Patel, D.D.2
Dryja, T.3
Wright, A.M.4
Koroleva, I.5
Bruin, G.6
Antoni, C.7
Draelos, Z.8
Gold, M.H.9
-
43
-
-
84873124241
-
Efficacy and safty of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study
-
Papp, K.A.; Langley, R.G.; Sigurgeirsson, B.; Abe, M.; Baker, D.R.; Konno, P.; Haemmerle, S.; Thurston, H.J.; Papavassilis, C.; Richards, H.B. Efficacy and safty of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br. J. Dermatol. 2013, 168, 412-421, doi:10.1111/bjd.12110.
-
(2013)
Br. J. Dermatol.
, vol.168
, pp. 412-421
-
-
Papp, K.A.1
Langley, R.G.2
Sigurgeirsson, B.3
Abe, M.4
Baker, D.R.5
Konno, P.6
Haemmerle, S.7
Thurston, H.J.8
Papavassilis, C.9
Richards, H.B.10
-
44
-
-
84904545875
-
Secukinumab in plaque psoriasis-Results of two phase 3 trials
-
Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; et al. Secukinumab in plaque psoriasis-Results of two phase 3 trials. N. Engl. J. Med. 2014, 371, 326-38, doi:10.1056/NEJMoa1314258.
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 326-338
-
-
Langley, R.G.1
Elewski, B.E.2
Lebwohl, M.3
Reich, K.4
Griffiths, C.E.5
Papp, K.6
Puig, L.7
Nakagawa, H.8
Spelman, L.9
Sigurgeirsson, B.10
-
45
-
-
84922933349
-
Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
-
Blauvelt, A.; Prinz, J.C.; Gottlieb, A.B.; Kingo, K.; Sofen, H.; Ruer-Mulard, M.; Singh, V.; Pathan, R.; Papavassilis, C.; Cooper, S.; et al. Secukinumab administration by pre-filled syringe: Efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br. J. Dermatol. 2015, 172, 484-493, doi:10.1111/bjd.13348.
-
(2015)
Br. J. Dermatol.
, vol.172
, pp. 484-493
-
-
Blauvelt, A.1
Prinz, J.C.2
Gottlieb, A.B.3
Kingo, K.4
Sofen, H.5
Ruer-Mulard, M.6
Singh, V.7
Pathan, R.8
Papavassilis, C.9
Cooper, S.10
-
46
-
-
84975815496
-
Brodalumab for the treatment of psoriasis: A review of phase III trials
-
Farahnik, B.; Beroukhim, K.; Abrouk, M.; Nakamura, M.; Zhu, T.H.; Singh, R.; Lee, K.; Bhutani, T.; Koo, J. Brodalumab for the treatment of psoriasis: A review of phase III trials. Dermatol. Ther. 2016, 6, 111-124, doi:10.1007/s13555-016-0121-x.
-
(2016)
Dermatol. Ther.
, vol.6
, pp. 111-124
-
-
Farahnik, B.1
Beroukhim, K.2
Abrouk, M.3
Nakamura, M.4
Zhu, T.H.5
Singh, R.6
Lee, K.7
Bhutani, T.8
Koo, J.9
-
47
-
-
84952025973
-
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
-
Baeten, D.; Sieper, J.; Braun, J.; Baraliakos, X.; Dougados, M.; Emery, P.; Deodhar, A.; Porter, B.; Martin, R.; Andersson, M.; et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N. Engl. J. Med. 2015, 373, 2534-2548, doi:10.1056/NEJMoa1505066.
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 2534-2548
-
-
Baeten, D.1
Sieper, J.2
Braun, J.3
Baraliakos, X.4
Dougados, M.5
Emery, P.6
Deodhar, A.7
Porter, B.8
Martin, R.9
Andersson, M.10
-
48
-
-
85018743344
-
The effect of body weight on the efficacy and safety of ixekizumab: Results from an integrated database of 3 randomized, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis
-
Reich, K.; Puig, L.; Mallbris, L.; Zhang, L.; Osuntokun, O.; Leonardi, C. The effect of body weight on the efficacy and safety of ixekizumab: Results from an integrated database of 3 randomized, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017, doi:10.1111/jdv.14252.
-
(2017)
J. Eur. Acad. Dermatol. Venereol.
-
-
Reich, K.1
Puig, L.2
Mallbris, L.3
Zhang, L.4
Osuntokun, O.5
Leonardi, C.6
-
49
-
-
37349131221
-
Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines
-
Fitch, E.; Harper, E.; Skorcheva, I.; Kurtz, S.E.; Blauvelt, A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr. Rheumatol. Rep. 2010, 9, 461-467.
-
(2010)
Curr. Rheumatol. Rep.
, vol.9
, pp. 461-467
-
-
Fitch, E.1
Harper, E.2
Skorcheva, I.3
Kurtz, S.E.4
Blauvelt, A.5
-
50
-
-
0347285359
-
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
-
Lee, E.; Trepicchio, W.L.; Oestreicher, J.L.; Pittman, D.; Wang, F.; Chamian, F.; Dhodapkar, M.; Krueger, J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 2004, 199, 125-130.
-
(2004)
J. Exp. Med.
, vol.199
, pp. 125-130
-
-
Lee, E.1
Trepicchio, W.L.2
Oestreicher, J.L.3
Pittman, D.4
Wang, F.5
Chamian, F.6
Dhodapkar, M.7
Krueger, J.G.8
-
51
-
-
43449111187
-
PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
Leonardi, C.L.; Kimball, A.B.; Papp, K.A.; Yeilding, N.; Guzzo, C.; Wang, Y.; Li, S.; Dooley, L.T.; Gordon, K.B. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371, 1665-1674, doi:10.1016/S0140-6736(08)60725-4.
-
(2008)
Lancet
, vol.371
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
Yeilding, N.4
Guzzo, C.5
Wang, Y.6
Li, S.7
Dooley, L.T.8
Gordon, K.B.9
-
52
-
-
43449139402
-
PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
-
Papp, K.A.; Langley, R.G.; Lebwohl, M.; Krueger, G.G.; Szapary, P.; Yeilding, N.; Guzzo, C.; Hsu, M.C.; Wang, Y.; Li, S.; et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371, 1675-1684, doi:10.1016/S0140-6736(08)60726-6.
-
(2008)
Lancet
, vol.371
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
Krueger, G.G.4
Szapary, P.5
Yeilding, N.6
Guzzo, C.7
Hsu, M.C.8
Wang, Y.9
Li, S.10
-
53
-
-
84883134297
-
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
-
McInnes, I.B.; Kavanaugh, A.; Gottlieb, A.B.; Puig, L.; Rahman, P.; Ritchlin, C.; Brodmerkel, C.; Li, S.; Wang, Y.; Mendelsohn, A.M.; et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382, 780-789, doi:10.1016/S0140-6736(13)60594-2.
-
(2013)
Lancet
, vol.382
, pp. 780-789
-
-
McInnes, I.B.1
Kavanaugh, A.2
Gottlieb, A.B.3
Puig, L.4
Rahman, P.5
Ritchlin, C.6
Brodmerkel, C.7
Li, S.8
Wang, Y.9
Mendelsohn, A.M.10
-
54
-
-
84899922972
-
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
-
Kavanaugh, A.; Ritchlin, C.; Rahman, P.; Puig, L.; Gottlieb, A.B.; Li, S.; Wang, Y.; Noonan, L.; Brodmerkel, C.; Song, M.; et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 2014, 73, 1000-1006, doi:10.1136/annrheumdis-2013-204741.
-
(2014)
Ann. Rheum. Dis.
, vol.73
, pp. 1000-1006
-
-
Kavanaugh, A.1
Ritchlin, C.2
Rahman, P.3
Puig, L.4
Gottlieb, A.B.5
Li, S.6
Wang, Y.7
Noonan, L.8
Brodmerkel, C.9
Song, M.10
-
55
-
-
84964836426
-
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebocontrolled studies (PSUMMIT-1/PSUMMIT-2)
-
Kavanaugh, A.; Puig, L.; Gottlieb, A.B.; Ritchlin, C.; You, Y.; Li, S.; Song, M.; Randazzo, B.; Rahman, P.; McInnes, I.B. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebocontrolled studies (PSUMMIT-1/PSUMMIT-2). Ann. Rheum. Dis. 2016, 75, 1984-1988, doi:10.1136/annrheumdis-2015-209068.
-
(2016)
Ann. Rheum. Dis.
, vol.75
, pp. 1984-1988
-
-
Kavanaugh, A.1
Puig, L.2
Gottlieb, A.B.3
Ritchlin, C.4
You, Y.5
Li, S.6
Song, M.7
Randazzo, B.8
Rahman, P.9
McInnes, I.B.10
-
56
-
-
84899991797
-
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial
-
Ritchlin, C.; Rahman, P.; Kavanaugh, A.; McInnes, I.B.; Puig, L.; Li, S.; Wang, Y.; Shen, Y.K.; Doyle, M.K.; Mendelsohn, A.M.; et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 2014, 73, 990-999, doi:10.1136/annrheumdis-2013-204655.
-
(2014)
Ann. Rheum. Dis.
, vol.73
, pp. 990-999
-
-
Ritchlin, C.1
Rahman, P.2
Kavanaugh, A.3
McInnes, I.B.4
Puig, L.5
Li, S.6
Wang, Y.7
Shen, Y.K.8
Doyle, M.K.9
Mendelsohn, A.M.10
-
57
-
-
84957865071
-
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature
-
Chimenti, M.S.; Talamonti, M.; Novelli, L.; Teoli, M.; Galluzzo, M.; Triggianese, P.; Perricone, R. Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature. J. Dermatol. Case Rep. 2015, 9, 71-75, doi:10.3315/jdcr.2015.1207.
-
(2015)
J. Dermatol. Case Rep.
, vol.9
, pp. 71-75
-
-
Chimenti, M.S.1
Talamonti, M.2
Novelli, L.3
Teoli, M.4
Galluzzo, M.5
Triggianese, P.6
Perricone, R.7
-
58
-
-
79955538365
-
Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity
-
Huh, J.R.; Leung, M.W.; Huang, P.; Ryan, D.A.; Krout, M.R.; Malapaka, R.R.; Chow, J.; Manel, N.; Ciofani, M.; Kim, S.V.; et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 2011, 472, 486-490, doi:10.1038/nature09978.
-
(2011)
Nature
, vol.472
, pp. 486-490
-
-
Huh, J.R.1
Leung, M.W.2
Huang, P.3
Ryan, D.A.4
Krout, M.R.5
Malapaka, R.R.6
Chow, J.7
Manel, N.8
Ciofani, M.9
Kim, S.V.10
-
59
-
-
80052423903
-
Structural basis of digoxin that antagonizes RORgamma T receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production
-
Fujita-Sato, S.; Ito, S.; Isobe, T.; Ohyama, T.; Wakabayashi, K.; Morishita, K.; Ando, O.; Isono, F. Structural basis of digoxin that antagonizes RORgamma T receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J. Biol. Chem. 2011, 286, 31409-31417, doi:10.1074/jbc.M111.254003.
-
(2011)
J. Biol. Chem.
, vol.286
, pp. 31409-31417
-
-
Fujita-Sato, S.1
Ito, S.2
Isobe, T.3
Ohyama, T.4
Wakabayashi, K.5
Morishita, K.6
Ando, O.7
Isono, F.8
-
60
-
-
84866532132
-
Induction and molecular signature of pathogenic TH17 cells
-
Lee, Y.; Awasthi, A.; Yosef, N.; Quintana, F.J.; Xiao, S.; Peters, A.; Wu, C.; Kleinewietfeld, M.; Kunder, S.; Hafler, D.A.; et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13, 991-999, doi:10.1038/ni.2416.
-
(2012)
Nat. Immunol.
, vol.13
, pp. 991-999
-
-
Lee, Y.1
Awasthi, A.2
Yosef, N.3
Quintana, F.J.4
Xiao, S.5
Peters, A.6
Wu, C.7
Kleinewietfeld, M.8
Kunder, S.9
Hafler, D.A.10
-
61
-
-
84876798411
-
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1
-
Wu, C.; Yosef, N.; Thalhamer, T.; Zhu, C.; Xiao, S.; Kishi, Y.; Regev, A.; Kuchroo, V.K. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 2013, 496, 513-517, doi:10.1038/nature11984.
-
(2013)
Nature
, vol.496
, pp. 513-517
-
-
Wu, C.1
Yosef, N.2
Thalhamer, T.3
Zhu, C.4
Xiao, S.5
Kishi, Y.6
Regev, A.7
Kuchroo, V.K.8
-
62
-
-
84949196321
-
CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity
-
Wang, C.; Yosef, N.; Gaublomme, J.; Wu, C.; Lee, Y.; Clish, C.B.; Kaminski, J.; Xiao, S.; Meyer, Z.; Horste, G.; et al. CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell 2015, 163, 1413-1427, doi:10.1016/j.cell.2015.10.068.
-
(2015)
Cell
, vol.163
, pp. 1413-1427
-
-
Wang, C.1
Yosef, N.2
Gaublomme, J.3
Wu, C.4
Lee, Y.5
Clish, C.B.6
Kaminski, J.7
Xiao, S.8
Meyer, Z.9
Horste, G.10
-
63
-
-
84992337491
-
Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17
-
Takaishi, M.; Ishizaki, M.; Suzuki, K.; Isobe, T.; Shimozato, T.; Sano, S. Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17. J. Dermatol. Sci. 2017, 85, 12-19, doi:10.1016/j.jdermsci.2016.10.001.
-
(2017)
J. Dermatol. Sci.
, vol.85
, pp. 12-19
-
-
Takaishi, M.1
Ishizaki, M.2
Suzuki, K.3
Isobe, T.4
Shimozato, T.5
Sano, S.6
|